BioStock: Chordate Medical advances to final phase of exit strategy

Chordate Medical has a clear goal of executing an exit and has now appointed Partner International Switzerland as an advisor to find a buyer and finalize the exit strategy. A key part of this strategy is to establish proof of concept in selected target markets for the migraine treatment Ozilia. Recently, the company has made significant progress in Saudi Arabia, where the migraine treatment has received market approval.

BioStock interviews Chordate Medical's CEO, Anders Weilandt, regarding the exit strategy and market advancements.

https://www.biostock.se/en/2024/10/chordate-medical-advances-to-final-phase-of-exit-strategy/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se